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Abstract Most patients with monosymptomatic nocturnal
enuresis can be effectively treated with an enuresis alarm or
antidiuretic therapy (desmopressin), depending on the patho-
physiology of the condition in the individual patient.
Desmopressin is first-line therapy for enuresis caused by noc-
turnal polyuria, an excessive urine output during the night.
However, in a recent study, around one-third of patients
thought to be resistant to desmopressin were subsequently
treated effectively with desmopressin monotherapy in a spe-
cialist centre. The aim of this article is to review best practice
in selecting patients for desmopressin treatment, as well as
outline eight recommendations for maximizing the chances
of treatment success in patients receiving desmopressin. The
roles of formulation, dose, timing of administration, food and
fluid intake, inter-individual variation in response, body
weight, adherence, withdrawal strategies and combination
therapies are discussed in light of the most recent research
on desmopressin and enuresis. Possible reasons for subopti-
mal treatment response are explored and strategies to improve
outcomes in patients for whom desmopressin is an appropriate
therapy are presented. Through optimization of the treatment
plan in primary and specialist care centres, the hope is that
fewer patients with this distressing and often embarrassing
condition will experience unnecessary delays in receiving ap-
propriate care and achieving improvements.
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Introduction
According to the International Children’s Continence
Society’s (ICCS) standardization of terminology [1], children
with nocturnal enuresis (NE) with concomitant symptoms of
lower urinary tract dysfunction differ clinically, therapeutical-
ly and in pathogenesis from children without daytime symp-
toms. Patients without daytime symptoms are categorized as
having monosymptomatic nocturnal enuresis (MNE), and
these patients are the focus of this review, although we do
touch upon the potential role of desmopressin in patients with
non-monosymptomatic NE (NMNE) whose daytime symp-
toms have been resolved.
MNE is generally a more straightforward condition than
NMNE to treat using one of two treatments with level 1 evi-
dence and grade A recommendations from the International
Consultation on Incontinence: enuresis alarm and
desmopressin [2, 3]. However, patients must be properly eval-
uated and diagnosed and therapy must be used appropriately
for the treatment to be successful [4]. Data show that proper
patient screening can predict treatment response, as well as
failure rates [5]. Furthermore, in a recent study of enuresis
patients with desmopressin resistance who had been referred
to a specialist centre, one-third of children (177/539) subse-
quently became dry on desmopressin monotherapy under spe-
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We therefore highlight the importance of appropriate
desmopressin usage and administration, and the failure of pri-
mary care centres to achieve optimal results with first-line
treatment is of concern. For many patients, enuresis and its
associated distress are unnecessarily prolonged despite being
prescribed a potentially effective treatment. The aim of this
review is to clarify best practice in the use and administration
of desmopressin for eligible enuresis patients.
MNE and its pathophysiology
Research has established that there are three key pathogenic
mechanisms underlying MNE:
1. Nocturnal polyuria (NP)
& The ICCS definition [nocturnal urine production
>130 % of expected bladder capacity (EBC) for age]
[1] is a relatively arbitrary cutoff, above which noc-
turnal urine production is considered abnormal
{EBC=[30× (age in years + 1)mL]}. To some extent
the EBC-based formula is supported by population
data [7].
& In the context of using NP as an index for good
desmopressin response, then we suggest that noctur-
nal diuresis of >100 % of EBC might be more appro-
priate for the clinician [5].
2. Reduced or abnormal bladder reservoir function at night
[8, 9] (including isolated reduced nocturnal bladder ca-
pacity (B. Borg, K. Kamperis, S. Rittig, unpublished
data).
3. Inability to wake in response to bladder signalling
Either (or both) of the first two issues may be present,
causing a mismatch between the volume of urine produced
overnight and the volume of urine the bladder can accommo-
date before emptying. However, for enuresis to result, rather
than nocturia, there must also be an impairment of arousal
from sleep with a full bladder.
Previous estimates have suggested that approximately two-
thirds of children with MNE have NP [3]. The true figure,
using current ICCS definitions, is likely to be lower, but it
can only be determined in a completely unselected population
for which data are not currently available.
It is widely accepted that nocturnal polyuria in the majority
of children is related to an insufficient nocturnal increase in
antidiuretic hormone, i.e., arginine vasopressin (AVP) [10,
11], causing a high diuresis rate with low osmolality over-
night. Other mechanisms might be involved, especially in
desmopressin-refractory patients, such as excessive evening
fluid intake or, more commonly, factors such as abnormal
circadian rhythm of osmotic excretion, natriuresis, excess
prostaglandin production or an abnormal circadian rhythm
of the glomerular filtration rate [12–14].
However, there is good evidence that the major pathoge-
netic factor in children with NP is decreased AVP overnight
[10, 11]. Secretion of this hormone usually increases during
sleep to allow a low volume and highly concentrated noctur-
nal urinary output. In many children with enuresis and NP, this
circadian rhythm is lacking. Children with NP are most likely
to benefit from desmopressin since lower nocturnal vasopres-
sin levels have been demonstrated in a large percentage of
patients [11], making substitution with desmopressin, a syn-
thetic analogue of AVP, a rational first-line treatment for chil-
dren with MNE and NP [3].
Children without NP are most likely to benefit from an
enuresis alarm. The alarm’s mechanism of effect is not fully
understood, but an increase in bladder storage capacities is
reported with its use [15, 16]. Despite good efficacy when
used appropriately and consistently, alarm treatment can pres-
ent a significant burden to the family, and discontinuation
rates are high [17].
Desmopressin profile
Formulations
Desmopressin is available as a solid tablet (0.2–0.6 mg), a
rapidly melting oral lyophilisate (120–360 μg) and an intra-
nasal spray. However, the NE indication has been withdrawn
from the intranasal spray in most countries due to unpredict-
ability of dosing and increased risk of hyponatremia [18].
Efficacy
Desmopressin was first indicated for NE in 1982. A large
body of research has demonstrated the drug’s efficacy
[19–21]. Reported response rates vary (e.g. only 41 % of
patients achieved ≥50 % reduction in wet nights in the study
by Lottman et al. [22], but 77 % achieved >90 % reduction in
the study by Onol and colleagues [17]), likely affected by the
type of patients selected, suboptimal adherence rates, admin-
istration methods and doses and formulations used. In general,
it is estimated that around 30 % of children with enuresis are
full responders to desmopressin and that 40 % have a partial
response to this AVP analogue [2].
Safety
Desmopressin is generally well tolerated [23]. A rare but se-
rious side effect is low serum sodium (hyponatremia); predis-
posing factors include excessive fluid intake, high doses, use
of the intranasal spray formulation (historically) and, in
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particular, concomitant medications or illnesses [18, 24].
However, if used correctly, oral desmopressin has a good
safety profile in children with MNE, regardless of age and
gender [18, 25].
According to ICCS recommendations, an evening fluid
intake of ≤200 ml and then no drinking until morning is a safe
guideline to minimize risk of hyponatremia [2]. In general
practice, it is commonly advised that patients should stop
drinking 2 h before bedtime, with desmopressin administra-
tion up to 1 h before bedtime. Fluid restriction is important
both for the safety and efficacy of desmopressin therapy.
Patients and medical professionals should be vigilant to symp-
toms such as nausea, headache and vomiting, especially dur-
ing the first 2 weeks following treatment initiation when
hyponatremia is most likely [26].
Which patients can benefit from desmopressin?
A post-hoc analysis of the large DRIP [Desmopressin
Response in PNE (primary nocturnal enuresis)] study demon-
strated the importance of selecting the right treatment for the
right patients, based upon a full non-invasive medical evalua-
tion, including a frequency–volume chart [5]. The original
DRIP study found that around 40 % of participants experi-
enced ≥50 % reduction in wet nights, a lower than expected
response rate [22]. Entry criteria for the study excluded those
with Bdaytime symptoms^, and all eligible subjects were con-
sidered to have MNE. However, strict ICCS criteria were not
applied as the study was designed and carried out prior to
publication of the 2006 standardization paper which clearly
defined characteristics of patients requiring an MNE versus
NMNE diagnosis.
A recent post-hoc analysis investigated parameters that
were predictive of response to desmopressin in the DRIP
study [5] and found that age was the only significant demo-
graphic predictor (increased efficacy with increased age).
Younger children are more prone to have a low maximum
voided volume (MVV) and/or overactive bladder symptoms
which are resistant to antidiuretic therapy [8, 27]. The rele-
vance of an interaction between food ingested and
desmopressin tablets is also greater for younger children (see
below), since they are likely to have a shorter interval between
their last meal and bedtime than older children. Controlling for
age, significant predictive clinical variables were number of
wet nights per week (increased efficacy with fewer wet
nights), average daytime voided volume, maximum daytime
voided volume, total daytime diuresis, nocturnal diuresis,
maximum 24 h voided volume and total 24 h diuresis. In fact,
>80% of children included in the DRIP study did not have NP
(using the definition proposed by Rittig [7]) and had a low
daytime MVV (using the definition proposed by Hjälmås
[28]), as shown in Table 1. This indicates that desmopressin
was not the most appropriate treatment for these children and
helps to explain the rather low response rate. The strongest
individual predictors of treatment success were increased noc-
turnal diuresis and fewer wet nights per week.
Previous studies have highlighted the influence of bladder
capacity (voided volumes) on response to desmopressin.
Patients with an MVVof >70 % of that expected for age are
twice as likely to respond to desmopressin compared with
patients with a reduced MVV [27]. Therefore, it is essential
that the treating physician recognize that desmopressin will
not work for all patients and that he/she does have some tools
to predict response. It is important that the most appropriate
treatment strategy is selected as quickly as possible in order to
minimize distress and difficulty for the patient and family.
Thorough history-taking is therefore required to identify com-
plicating factors, such as constipation, psychological prob-
lems, daytime urinary symptoms, among others, which should
be addressed first and/or which indicate a need for referral for
specialist evaluation [4].
The use of bladder diaries is highly recommended wherev-
er possible [4]. This should include a daytime diary (frequen-
cy–volume chart) documenting void volumes and times and
fluid intake over a 4-day period, which is sufficient time to
allow an evaluation of MVV [29]. Although the ICCS advises
the exclusion of the first morning void [1], we recommend that
it should be included for the MVV to be predictive of
desmopressin response [5, 30]. We recognize that the ICCS
standardization recommends the use of 2-day diaries, which
represent a compromise between optimal and minimal regis-
tration during screening [1]. However, we advocate the longer
4-day diaries to optimize reliability since there is high intra-
individual variability [29]. In addition, a bedwetting diary
should be completed, documenting wet nights, urine volumes
(or diaper weight) and time in bed for 7 consecutive nights;
this diary enables the detection of NP. The volume of the first
morning void (in ml) should be added to the difference in
diaper weight to calculate nighttime urine production. In pa-
tients with nocturia, the volume of nighttime voids should be
added [4]. Nocturnal urine volumes greater than the EBC are
suggestive of NP. Note, however, that NP should be expected
only on wet nights.
Once the results of these assessments are available, issues
such as undetected daytime symptoms (NMNE) and other
known predictors of treatment resistance can be identified,
and suitability of the patient for desmopressin or the enuresis
alarm can be gauged [4] (Table 2).
The ICCS provides standardized definitions of treatment
success and treatment response for research purposes.
However, in the clinical scenario it is the affected child and
family who decide appropriate criteria for treatment success
[1], and patients and carers should be encouraged to return to
clinic if they are not satisfied with the level of response
achieved.
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How to maximize desmopressin success in the right
patient
Taking into account pathophysiology and predictors of treat-
ment success, the Btextbook^ candidate for desmopressin
treatment:
– has NP and normal (or large) MVV based on diaries [27]
– may be at the older end of the affected age range [5, 27]
(due to increased food interaction and prevalence of over-
active bladder (OAB) in younger children)
– may have less severe NE [5]
Once patients have been identified as likely to benefit from
desmopressin a number of important considerations can help
to achieve clinical response and may improve response in
those who appear desmopressin-resistant or partially resistant
(see Table 3 for summary).
Recommendation 1: Select the most appropriate
formulation—most often the oral lyophilisate formulation
There are several practical and physiological reasons why the
oral lyophilisate formulation of desmopressin is in most cases
the preferred formulation for children with MNE. These
include:
1. Oral lyophilisate formulations are easy for children to
take, and recommended for the pediatric population [31].
2. The oral lyophilisate formulation of desmopressin is pre-
ferred to the tablet, by children <12 years [32].
3. No water is required, leading to:
– reduced diuresis
– reduced fluid intake (as recommended to minimize
hyponatremia risk and increase efficacy)
– increased convenience.
4. Low food interaction is seen with the oral lyophilisate
versus tablet [33], reducing difficulties posed by the
short interval between the evening meal and bedtime
for young children (see Recommendation 2).
Efficacy There is some evidence that the oral lyophilisate
may, despite bioequivalent dosing, achieve a greater reduction
in the number of wet nights than the tablet [34]. This may be a
result of the different pharmacokinetic and pharmacodynamic
characteristics of the oral lyophilisate, administration method
and/or effects of the formulation on adherence (discussed later
in this review).
Bioavailability and predictability of dosing The oral
lyophilisate’s higher bioavailability compared with the tablet
allows lower dosing for optimal efficacy (thereby reducing the
risk of side effects) [35]. It has been demonstrated that noc-
turnal urine production during desmopressin treatment is sig-
nificantly greater during wet nights than during dry nights [36,
37], indicating nightly intra-individual variation in the
antidiuretic effect (and therefore anti-enuretic effect) of
desmopressin. The pharmacokinetics of desmopressin oral
lyophilisate are more predictable than those of the tablet for-
mulation, with smaller variances in plasma concentration [38],
which may lead to reduced intra-individual variability and
greater consistency of the antidiuretic effect.
Table 1 Nocturnal polyuria and
maximum voided volume status
of children included in the DRIP
studya
Nocturnal polyuria Normal or high maximum
voided volume
Low maximum voided volumeb
i.e. below [30 + (age × 30) ]
Nocturnal polyuriac
i.e. nocturnal urine volume of
more than [20 × (age + 9) ml ]
3.16 % 9.63 %
No nocturnal polyuria 6.98 % 80.23 %
aDRIP [Desmopressin Response in PNE (primary nocturnal enuresis)] study (Lottmann et al. [22])
b Low maximum voided volume defined using cut-off proposed by Hjälmås [28]
c Nocturnal polyuria (NP) is defined using cutoff proposed by Rittig et al. [7]
Table 2 First-line treatment choice based on nocturnal polyuria and
maximum voided volume status
Presentation Recommended first-line treatment
NP on wet nights Low MVV Desmopressin Alarm
✓ x ✓
x ✓ ✓
x x ✓ or ✓
✓ ✓ ✓ and ✓
MVV, Maximum voided volume
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Recommendation 2: Ensure optimal timing
of administration and consider possible impact of meals
The desmopressin tablet and oral lyophilisate should be ad-
ministered 60 min before bedtime [2, 35]. However, in prac-
tice, many patients take desmopressin at bedtime. The clinical
relevance of this common non-adherence to recommendations
has not been fully explored. and future studies aimed at ex-
amining any impact on the drug’s efficacy would be helpful to
clarify the importance of a 1-h interval between desmopressin
administration and bedtime.
Additionally, patients are advised to take desmopressin at
least 2 h after the evening meal. If the drug is to be taken 1 h
before bedtime, there must be a 3-h interval overall between
the evening meal and bedtime, which may be impractical in
school-aged children. The timing of medication administra-
tion is therefore likely, in reality, to fall short of recommended
best practice, with food and desmopressin intake occurring at
a similar time. Pharmacodynamic data show that the oral
lyophilisate (120 μg) may be more effective and predictable
than the bioequivalent 0.2 mg tablet when administered after a
meal [33], with a significant increase in duration of action and
indications of a shorter time to reach maximal antidiuresis and
a higher concentrating capacity. Variability (standard devia-
tion) in the diuresis rate was also lower with the oral
lyophilisate, likely due to less interference with nutrition since
the oral lyophilisate is believed to be reabsorbed by oral and/or
oesophageal mucosa. Although to date no studies have proven
this difference to be relevant for the clinical effect of the for-
mulations, it may be an important factor for young children
because of their early bedtime.
Furthermore, because the oral lyophilisate is believed to be
absorbed by oral and/or oesophageal mucosa, it is likely to be
less affected by intestinal motility. However, the absorption of
desmopressin tablets increases if intestinal motility is delayed
[39].
Additional consideration should be given to the possible
impact of diet and daytime fluid intake on osmotic load and
NE. Some children with desmopressin-resistant NP have high
osmotic excretion during the night, possibly due to a high
osmotic load of protein and sodium during the evening meal
[12]. Other children with NPmay have high osmotic excretion
at night but deficient osmotic excretion during the day, possi-
bly caused by extremely low daytime fluid intake to compen-
sate for a small bladder capacity. Adaptations to nutritional
and fluid intake may therefore be helpful in improving NE
in some cases.
Recommendation 3: Ensure fluid restriction before and
after desmopressin administration
Suboptimal response to desmopressin can also be worsened
by failure to restrict fluid intake before the administration of
desmopressin [40]. Clear instructions should be given to
Table 3 Summary of important
considerations to take into
account for treatment success
with desmopressin
Consideration Description or recommended action
Does patient have monosymptomatic NE? History taking, frequency–volume chart
(daytime symptoms, low MVV?)
Does patient have NP? Diagnosed using bedwetting diary
Is the most appropriate formulation of
desmopressin being prescribed?
Usually oral lyophilisate (higher bioavailability,
predictability, less food interaction)
Timing of desmopressin administration Ideally to be taken 1 h before bedtime and 2 h
after food; oral lyophilisate should be used if
shorter interval due to reduced food interaction.
Some patients may take longer to reach maximum
concentrating capacity; then try earlier administration
Fluid intake Limit fluid intake from 1 h before to 8 h after
administration
Desmopressin dose—is duration of
action sufficient?
Inter-individual variation in desmopressin response
means dose adjustment often required (Fig. 1);
pharmacodynamic testing may be helpful
Body weight Body weight may influence required dose with oral
lyophilisate
Is patient adherent? Adherence to treatment and administration
recommendations is crucial but often suboptimal
Does patient want to stop treatment? Structured/tapered withdrawal may be tried to
avoid relapse
Combination therapy Additional therapies may help in desmopressin-
resistant patients or those with partial response
NE nocturnal enuresis; NP nocturnal polyuria; MVV maximum voided volume
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patients regarding fluid restriction (for efficacy and safety rea-
sons) from 1 h before desmopressin is administered and for
8 h subsequently to encourage optimal concentrating capacity
and treatment response, as well as to reduce the risk of
hyponatremia/water intoxication. Patients should also be sure
to go to the toilet for their final void of the day immediately
before going to sleep.
Recommendation 4: If necessary, tailor treatment dose
and timing to the response of the individual
The dose–response effect of desmopressin is seen not only in
the level of antidiuresis achieved, but primarily in the duration
of action [23]. Even at low doses, maximal antidiuresis is
demonstrated, but the duration of this activity is dependent
on the exposure to desmopressin, i.e. overdosing results in
prolonged activity [41]. For children with MNE, the clinically
relevant period is 7–11 h, i.e. equivalent to a night’s sleep. A
duration of action exceeding the normal duration of a night
will increase the risk of undesired prolonged antidiuresis.
Pharmacodynamic data available for the lyophilisate formula-
tion indicate that a small dose range (120–240 μg) is likely to
control diuresis for a period corresponding to a night’s sleep
(mean of 7–11 h) in most children with PNE [35]. A flow-
chart which can be used to guide dose adjustments when pre-
scribing the oral lyophilisate is shown in Fig. 1.
However, the inter-individual range of duration of activity is
large, and an individual approach may be needed. Registry data
from Denmark on desmopressin prescriptions for NE show that
among 40,596 patients, 66 % used the oral lyophilisate, 18 %
used tablets and 17 % used the nasal spray. Among those using
the lyophilisate, 26 % used 60 μg—i.e. below the recommend-
ed minimum dose in Denmark (M. Schroeder, K, Juul, J.P.
Norgaard, S. Rittig, unpublished data), suggesting this dose
was sufficient for many patients. Indeed, patients with NE
and NP can differ in their response to desmopressin. Time to
reach maximal antidiuretic effect and the duration of pharma-
codynamic action show a wide range, and there is inter-
individual variation in the duration of effect [40].
Individualized tailoring and titration of dose (and hence dura-
tion of action)may therefore help to achieve efficacy in partially
resistant patients [40]. A simple pharmacodynamic test based
on home recordings may provide important information on
optimal time of dosing, duration of action and influence of oral
fluid intake, thereby allowing optimization of therapy. Due to
the documented prolonged action of desmopressin in some pa-
tients, pharmacodynamic testing is required before the dose is
increased above recommended levels; such testing should only
be considered in specialist centres.
As discussed in previous sections, data show that
desmopressin should be administered at least 1 h before bed-
time to achieve optimal efficacy during sleep [35, 40]. In cases
of therapy resistance, a longer interval between administration
and bedtime (up to 2 h) might further reduce the diuresis rate in
the early night for children who take longer to reach maximal
concentrating capacity [40]. In support of this proposal, time to
reach maximum antidiuretic action was found to be around 2 h
in a group of children with MNE and NP who had inadequate
response to desmopressin intranasal spray [40]. However, no
controlled studies on increasing the interval between drug ad-
ministration and bedtime have been performed, and it is possi-
ble that earlier dosing would also lead to loss of therapeutic
effect before it is time for the child to rise in the morning.
In some cases, poor treatment response due to an insuffi-
cient pharmacodynamic effect of desmopressin may be related
to an inappropriate renal response with suboptimal maximal
renal concentrating capacity [40], and factors such as large
osmotic load, natriuresis and hypercalcaemia may play a role
[14, 42]; an individual approach is recommended in these
patients.
Recommendation 5: Consider the possible impact of body
weight
There is a positive correlation between the plasma concentra-
tion of desmopressin and the dose corrected byweight at 2 and
6 h post-dosing using the oral lyophilisate in children, but this
weight-dependency is not seen for the tablet (nor for the in-
tranasal spray) [38]. It has been suggested that the lack of
evidence for a size effect with the administration of the tablet
and the intranasal spray should be attributed to the poor pre-
dictability of their bioavailability, which may mask the size
effect. If using the oral lyophilisate, therefore, it is possible
that dose may need to be adapted to body weight if initial
efficacy is suboptimal (see Recommendation 4).
Recommendation 6. Ensure patients are adherent
to treatment and administration recommendations
Desmopressin is only effective on the night following its ad-
ministration and, consequently high levels of adherence are
necessary to maintain a good response each and every night.
However, in almost every therapy area, and particularly chron-
ic conditions, adherence levels are suboptimal; around 50 %
of patients do not take their medications as prescribed [43]. In
a report on adherence, the World Health Organization quoted
a statement by Haynes et al. that: Bincreasing the effectiveness
of adherence interventions may have a far greater impact on
the health of the population than any improvement in specific
medical treatments.^
In the DRIP trial, where desmopressin tablets were used,
81–91 % of patients ingested all medication as instructed dur-
ing the initial run-in [44]. This decreased to 77 and 71 %
during the first and second 3-month treatment periods, respec-
tively. Despite the closely monitored setting of a clinical trial,
therefore, up to around 20 % of patients were not fully
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adherent to treatment, even during the run-in phase, and over
30 %were not fully adherent at later stages. Poor adherence to
treatment could therefore explain a poor response in some
patients since the reduction in wet nights/week, as would be
expected, is significantly greater for a higher adherence rate
compared with lower adherence [34, 44]. It is crucial that
clinicians advise patients of the importance of full adherence
with desmopressin therapy, as well as adherence with the in-
structions regarding the timings of desmopressin administra-
tion, fluid intake, among other factors (discussed earlier in this
review) to achieve the best possible efficacy. Ongoing clinical
support and monitoring may help to facilitate this.
There are some data to suggest that adherence to treatment
increases when patients are switched from the tablet to the oral
lyophilisate formulation of desmopressin [34]. This, coupled
with younger children’s preference for the lyophilisate [32],
suggests it may contribute to improved outcomes via higher
adherence levels.
Recommendation 7. If cessation of treatment is desired,
consider a structured withdrawal programme
Following achievement of response to desmopressin, it is gen-
erally considered that continued treatment is required to avoid
relapse, given that the drug only has an effect on the night
following its administration for approximately 7–11 h.
Regular drug holidays are recommended to evaluate whether
treatment can be discontinued. There have been a small num-
ber of studies reporting that a gradual or tapered withdrawal of
desmopressin over several weeks can reduce relapse com-
pared with abrupt termination of therapy in patients using
the lyophilisate [45, 46] and the tablet [47]. Other studies have
failed to replicate this effect [48], and the mechanism of con-
tinued antidiuretic effect after withdrawal of treatment is not
yet understood.
Recommendation 8: Consider combination therapy where
appropriate
It is possible that, in some patients, desmopressin has an
antidiuretic effect but not an anti-enuretic effect—i.e. that despite
reduced diuresis, bladder dysfunction still causes the bladder to
empty prematurely (and patients do not wake in response to
bladder signalling). Some patients have an isolated low bladder
capacity which is limited to the nighttime and would not there-
fore present with daytime urinary symptoms or be identified as
having NMNE (B. Borg, K. Kamperis, S. Rittig, unpublished
data). In such patients, home recordings are recommended while
the patient is receiving desmopressin to investigate how treat-
ment may be optimized. Accurate differentiation between
Inial dose 120 μg for 2 weeks
Dry?
Connue for 3 months
Yes No
Increase dose to 240μg for 2 weeks 
Dry?
Treatment break for 1 week
Dry?




Fig. 1 Dosing with desmopressin oral lyophilisate
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inadequate antidiuretic versus anti-enuretic response to
desmopressin can help inform subsequent treatment choices.
For some patients with confirmed MNE and NP, combination
therapymay be appropriate to achieve a good response (Table 4).
Such combinations should be considered only in specialist cen-
tres, with the exception of desmopressin combined with an en-
uresis alarm which can be used in primary care.
Persistent lack of response
For some patients, despite optimization of the desmopressin
regimen as described, there may still be a lack of effect. The
reasons for no response or partial response include various
factors. For example, the antidiuretic effect may be subopti-
mal, perhaps due to renal factors or an individual need for
higher dosing. Desmopressin may have been inappropriately
selected, as when the child has daytime urinary symptoms,
especially as these may be masked by reduced daytime fluid
intake. In this case, alternative treatment should be sought.
Poor adherence to treatment or to administration recommen-
dations (e.g. timing, fluid intake) may lead to poor effect, even
though desmopressin is an appropriate therapy. Alternatively,
if the patient has low nocturnal bladder capacity, alternative or
additional treatments may be needed.
Conclusions
In most cases, MNE can be treated successfully in primary
care with an enuresis alarm or desmopressin. For treatment
with desmopressin to be successful, the patient should fulfil
the characteristics required for response (i.e. NP, and no
NMNE) and be fully adherent to treatment and recommenda-
tions regarding the administration and food/fluid intake.
A surprisingly high proportion of patients who are believed
to be initially resistant to desmopressin are, in fact, treated suc-
cessfully with desmopressin monotherapy under specialist care.
In this review, we have outlined eight key recommendations for
the optimization of the desmopressin regimen to achieve the
most successful outcome for each patient receiving the drug.
The oral lyophilisate formulation is recommended for initial
treatment due to several pharmacodynamic, pharmacokinetic
and practical characteristics which render it superior to the tab-
let formulation, such as bioavailability, reduced variability, re-
duced interference from food, administration without water and
increased adherence. However, there may be individual reasons
(e.g. cost, preference) which would favour starting with, or
switching to, another formulation. Incorporation of the recom-
mendations included in this review into standard clinical prac-
tice should help to improve response to desmopressin for pa-
tients where it is the appropriate treatment; continued poor re-
sponse despite following these recommendations indicates the
need to explore alternative therapeutic strategies.
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